These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 12591750

  • 1. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
    Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators Group.
    Circulation; 2003 Feb 18; 107(6):817-23. PubMed ID: 12591750
    [Abstract] [Full Text] [Related]

  • 2. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
    Ruzyllo W, Tendera M, Ford I, Fox KM.
    Drugs; 2007 Feb 18; 67(3):393-405. PubMed ID: 17335297
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.
    Tardif JC, Ponikowski P, Kahan T, ASSOCIATE Study Investigators.
    Eur Heart J; 2009 Mar 18; 30(5):540-8. PubMed ID: 19136486
    [Abstract] [Full Text] [Related]

  • 4. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group.
    Frishman WH, Pepine CJ, Weiss RJ, Baiker WM.
    J Am Coll Cardiol; 1995 Aug 18; 26(2):305-12. PubMed ID: 7608428
    [Abstract] [Full Text] [Related]

  • 5. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study.
    Tardif JC, Ponikowski P, Kahan T, ASSOCIATE Investigators.
    Int J Cardiol; 2013 Sep 30; 168(2):789-94. PubMed ID: 23138014
    [Abstract] [Full Text] [Related]

  • 6. Heart rate slowing versus other pharmacological antianginal strategies.
    Diaz A, Tardif JC.
    Adv Cardiol; 2006 Sep 30; 43():65-78. PubMed ID: 16936473
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
    Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, INITIATIVE Investigators.
    Eur Heart J; 2005 Dec 30; 26(23):2529-36. PubMed ID: 16214830
    [Abstract] [Full Text] [Related]

  • 10. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U, Ezekowitz M, Fenney L, Chiang YK.
    Circulation; 1994 Aug 30; 90(2):726-34. PubMed ID: 8044941
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S, Timmis AD.
    Int J Clin Pract; 2006 Feb 30; 60(2):222-8. PubMed ID: 16451297
    [Abstract] [Full Text] [Related]

  • 13. Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.
    Jedlickova L, Merkovska L, Jackova L, Janicko M, Fedacko J, Novakova B, Chmelarova A, Majernik J, Pella D.
    Adv Ther; 2015 Oct 30; 32(10):962-70. PubMed ID: 26525390
    [Abstract] [Full Text] [Related]

  • 14. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D, Camm JA.
    Drugs; 2004 Oct 30; 64(16):1757-65. PubMed ID: 15301560
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR.
    J Cardiovasc Pharmacol Ther; 2004 Sep 30; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
    Tendera M, Borer JS, Tardif JC.
    Cardiology; 2009 Sep 30; 114(2):116-25. PubMed ID: 19468225
    [Abstract] [Full Text] [Related]

  • 17. Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina.
    Fox K.
    Expert Opin Pharmacother; 2006 Jun 30; 7(9):1211-20. PubMed ID: 16732707
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
    Borer JS, Tardif JC.
    Am J Cardiol; 2010 Jan 01; 105(1):29-35. PubMed ID: 20102886
    [Abstract] [Full Text] [Related]

  • 19. Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina.
    Glasser SP, Ripa S, Garland WT, Weiss R, Nademanee K, Singh S, Bittar N.
    J Clin Pharmacol; 1995 Aug 01; 35(8):780-4. PubMed ID: 8522634
    [Abstract] [Full Text] [Related]

  • 20. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris.
    Thadani U, Zellner SR, Glasser S, Bittar N, Montoro R, Miller AB, Chaitman B, Schulman P, Stahl A, DiBianco R.
    Circulation; 1991 Dec 01; 84(6):2398-408. PubMed ID: 1959195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.